Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NFKB2
REST API REST API
Homo sapiens
NFKB2 is differentially expressed in 285 experiments: 110 organism parts: liver, lung, ... (108 more);, 201 disease states: normal, chronic lymphocytic leukemia, ... (199 more);, 89 cell types 335 cell lines 43 compound treatments and 78 other conditions.
Synonyms p52, LYT-10
Orthologs NFKB2 (Bos taurus)   D4A9C5_RAT (Rattus norvegicus)   nfkb2 (Danio rerio)   Nfkb2 (Mus musculus)   Q4H348_CIOIN (Ciona intestinalis)   NFKB2 (Gallus gallus)   Nfkb2 (Rattus norvegicus)   Rel (Drosophila melanogaster)   nfkb2 (Xenopus laevis)   NFKB2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, cytosol, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, innate immune response, transcription, DNA-dependent, transcription coactivator activity, nucleus, positive regulation of NF-kappaB transcription factor activity, nucleoplasm, extracellular matrix organization, signal transduction, germinal center formation, toll-like receptor 4 signaling pathway, toll-like receptor signaling pathway, spleen development, toll-like receptor 3 signaling pathway, toll-like receptor 2 signaling pathway, Bcl3/NF-kappaB2 complex, MyD88-dependent toll-like receptor signaling pathway, follicular dendritic cell differentiation, sequence-specific DNA binding transcription factor activity, MyD88-independent toll-like receptor signaling pathway, toll-like receptor 1 signaling pathway
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom, RHD, NF_Rel_dor, Death, IPT_TIG_rcpt
UniProt Accession Q00653, A8K9D9, D3DR86
Search EB-eye ENSG00000077150
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SF-268
1
E-MTAB-62
ew24 cell line, lentivirus treated
1
E-MTAB-62
NCU-MM1
1
E-MTAB-62
SKMEL1
1
E-MTAB-37
329 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
3
2
E-AFMX-5, E-TABM-145
not specified
2
E-GEOD-18811, E-GEOD-11755
intraepithelial cytotoxic T lymphocyte
1
E-GEOD-4592
83 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-1869, E-GEOD-2466, ... (48 experiments)

Factor Value U/D Experiments
myeloma
2
E-MTAB-62, E-MTAB-37
Burkitt's lymphoma
2
E-GEOD-1880, E-MTAB-37
Raji Burkitt's lymphoma
2
E-AFMX-5, E-TABM-145
acute promyelocytic leukemia
2
E-GEOD-995, E-GEOD-1729
control
2
E-GEOD-21912, E-GEOD-16363
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
195 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-TABM-868, E-MEXP-1958, ... (30 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-2638
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
mercaptopurine, methotrexate
1
E-GEOD-412
tumor necrosis factor
1
E-GEOD-2638
endotoxin
1
E-GEOD-2322
17beta-estradiol
4
1
E-GEOD-2292
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-22513, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-4667, E-GEOD-3891, E-MEXP-2283, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-22541, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5809, E-GEOD-13073, E-GEOD-5681, E-GEOD-20540, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-740, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636, E-GEOD-2487

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-4922

Processing time: 0.538 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM